Morais TS - Search Results

1

Dual FGFR-targeting and pH-activatable ruthenium-peptide conjugates for targeted therapy of breast cancer.

Franco Machado J, Sá M, Pires I, da Silva MT, Marques F, Coelho JAS, Mendes F, Piedade MFM, Machuqueiro M, Jiménez MA, Garcia MH, Correia JDG, Morais TS. Franco Machado J, et al. Among authors: morais ts. Dalton Trans. 2024 May 7;53(18):7682-7693. doi: 10.1039/d4dt00497c. Dalton Trans. 2024. PMID: 38573236

2

Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer.

Franco Machado J , Machuqueiro M , Marques F , Robalo MP , Piedade MFM , Garcia MH , Correia JDG , Morais TS . Franco Machado J , et al. Among authors: morais ts. Dalton Trans. 2020 May 14;49(18):5974-5987. doi: 10.1039/d0dt00955e. Epub 2020 Apr 21. Dalton Trans. 2020. PMID: 32314752

3

New copper(I) complexes selective for prostate cancer cells.

Machado JF , Sequeira D , Marques F , Piedade MFM , Villa de Brito MJ , Helena Garcia M , Fernandes AR , Morais TS . Machado JF , et al. Among authors: morais ts. Dalton Trans. 2020 Sep 15;49(35):12273-12286. doi: 10.1039/d0dt02157a. Dalton Trans. 2020. PMID: 32839796

4

Cu(I) complexes as new antiproliferative agents against sensitive and doxorubicin resistant colorectal cancer cells: synthesis, characterization, and mechanisms of action.

Sequeira D, Baptista PV, Valente R, Piedade MFM, Garcia MH, Morais TS, Fernandes AR. Sequeira D, et al. Among authors: morais ts. Dalton Trans. 2021 Feb 9;50(5):1845-1865. doi: 10.1039/d0dt03566a. Dalton Trans. 2021. PMID: 33470993

5

Are smart delivery systems the solution to overcome the lack of selectivity of current metallodrugs in cancer therapy?

Franco Machado J, Morais TS. Franco Machado J, et al. Among authors: morais ts. Dalton Trans. 2022 Feb 14;51(7):2593-2609. doi: 10.1039/d1dt04079k. Dalton Trans. 2022. PMID: 35106525 Review.

6

Important cytotoxic and cytostatic effects of new copper(i)-phosphane compounds with N,N, N,O and N,S bidentate ligands.

Morais TS, Jousseaume Y, M Piedade MF, Roma-Rodrigues C, Fernandes AR, Marques F, Villa de Brito MJ, Garcia MH. Morais TS, et al. Dalton Trans. 2018 Jun 12;47(23):7819-7829. doi: 10.1039/c8dt01653d. Dalton Trans. 2018. PMID: 29850763

7

Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.

Machado JF, Correia JDG, Morais TS. Machado JF, et al. Among authors: morais ts. Molecules. 2021 May 25;26(11):3153. doi: 10.3390/molecules26113153. Molecules. 2021. PMID: 34070457 Free PMC article. Review.

8

Design and Anticancer Properties of New Water-Soluble Ruthenium-Cyclopentadienyl Complexes.

Morais TS, Marques F, Madeira PJA, Robalo MP, Garcia MH. Morais TS, et al. Pharmaceuticals (Basel). 2022 Jul 14;15(7):862. doi: 10.3390/ph15070862. Pharmaceuticals (Basel). 2022. PMID: 35890160 Free PMC article.

9

[RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.

Tomaz AI, Jakusch T, Morais TS, Marques F, de Almeida RF, Mendes F, Enyedy EA, Santos I, Pessoa JC, Kiss T, Garcia MH. Tomaz AI, et al. Among authors: morais ts. J Inorg Biochem. 2012 Dec;117:261-9. doi: 10.1016/j.jinorgbio.2012.06.016. Epub 2012 Jul 6. J Inorg Biochem. 2012. PMID: 22877927

10

Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes.

Côrte-Real L, Mendes F, Coimbra J, Morais TS, Tomaz AI, Valente A, Garcia MH, Santos I, Bicho M, Marques F. Côrte-Real L, et al. Among authors: morais ts. J Biol Inorg Chem. 2014 Aug;19(6):853-67. doi: 10.1007/s00775-014-1120-y. Epub 2014 Feb 23. J Biol Inorg Chem. 2014. PMID: 24562604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page